EUCTR2022-000302-10-CZ进行中（未招募）1 期
Significance of T cell response to vaccination against SARS-CoV2 for leukemic patients with weakend immune system - UHKT-COVID19
Institute of hematology and blood transfusion0 个研究点目标入组 30 人开始时间: 2022年1月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Adult recipients of cell therapy (allo-HSCT, CAR19 T cells) indicated to vaccination against COVID19. 30 patients, 20 healthy volunteers vaccinated against COVID19.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •Uncompleted vaccination schedule.
研究者
相似试验
进行中（未招募）
1 期
Study of immune responses after vaccination with an influenza vaccine (Inflexal V) in patients who have undergone hematopoietic allogeneic stem cell transplantation.Allogeneic stem cell transplantationEUCTR2013-003403-19-SEKarolinska University Hospital30
尚未招募
不适用
Safety and efficacy of vaccination with T cell-dependent and T cell-independent primary and recall antigens in patients with rheumatoid arthritis treated with anti TNF-* antibodies (adalimumab) or anti B cell therapy (Rituximab).Rheumatoid arthritis RA Vaccination100038161000225210023213NL-OMON30739Academisch Medisch Centrum40
尚未招募
不适用
Post vaccination immunological response and immune monitoring for SARS-CoV-2CTRI/2021/08/035338Medanta Institute of Education and Research
Unknown
不适用
Immunogenicity of Influenza Vaccine in Long Term CareInfluenzaNCT02933723Insight Therapeutics, LLC200
招募中
3 期
Immunological responses and adverse reactions of the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare workers of Faculty of Medicine, Naresuan University.Assessing the immunological responses and adverse reactions elicited by the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccinationCOVID-19SAR-CoV-2 second booster doseheterologous vaccinationBNT162b2CoronaVachealthcare workersTCTR20221112001The National Science Research and Innovation Fund340